IPO Databook: Retension Pharmaceuticals (RTSN US) - Oct 2026

• Retension Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing medicines for hypertension and cardiovascular diseases. Its product candidate, RTN-001, is a next-generation, once-daily, oral, small molecule PDE-5 inhibitor.
• RTN-001 achieved clinically meaningful reductions in SBP and DBP in two Phase 2 pilot trials, with initial Phase 2b data expected in 2027. A patent extends protection to 2044.
• The company reported cash and cash equivalents of $13,493 thousand, but recurring losses raise substantial doubt about its ability to continue as a going concern.

This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.